

The Fritsma Factor

YOUR INTERACTIVE HEMOSTASIS RESOURCE

Cheat Sheet—July 1, 2022



Welcome to our July 2022 Fritsma Factor Cheat Sheet. This summer we experience the return to in-person meetings including the upcoming ISTH meeting July 9–13 in London; AACC, July 24–28, Chicago; and THSNA, August 18–19, also in Chicago.

June and July 2022 Quick Questions

Our June 2022 Quick Question asked, “What viscoelastometry [VET] equipment is employed in your ER or OR?” I reported your responses in my presentation, “*Operating Room Hemostasis Testing*” at the [ASCLS Joint Annual Meeting](#) Grand Rapids, Michigan, USA where I presented a talk on VET’s application to blood product and anticoagulant management. The [summary of our responses](#) is available on Fritsma Factor.

Our July 2022 Quick Question asks, “What von Willebrand disease [VWD] subtype is identified using the reduced concentration ristocetin-induced platelet aggregometry [RIPA] test?” Many of the VWD types and subtypes are currently identified by molecular diagnosis, however, the “legacy” phenotypic tests often provide a speedy and inexpensive shortcut. This may be one such case. Please select your answer on the right and add your comment below.

Coming Events

Fritsma Factor [links the first of three-part “Coag Conversations” webinar](#) featuring **Brandon M. Henry, MD**, entitled “*What have we learned about inflammation and thrombosis since the COVID-19 outbreak?*” Dr. Henry is a physician scientist and investigative pathologist affiliated with the Cincinnati Children’s Hospital Medical Center. The second segment of the series appears July 16, 2022.

ISTH 2022 is July 9–13, 2022 in London. Our Fritsma Factor sponsors Precision BioLogic and Affinity Biologicals invite attendees to drop by Booth 1210 to learn about our new products. PBI and Affinity authors will present two posters Tuesday July 12, 6:30–7:30 pm. Please drop by to speak with the authors.

- PB1177: Performance of FVIII Deficient Plasma with VWF in the Activity Measurement of FVIII Replacement Products in Plasma Samples Using an OSC Assay
- PB1183: Performance of a Chromogenic Factor IX Activity Assay in the Recovery of Factor IX Replacement Therapies

Thank you for your loyalty to The Fritsma Factor.

George A. Fritsma MS, MLS
The Fritsma Factor, Your Interactive Hemostasis Resource
www.fritsmafactor.com, george@fritsmafactor.com